Bristol-Myers Squibb Company (BMY) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
Bristol-Myers Squibb Company (BMY) Profile & Business Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Key Information
| Ticker | BMY |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.bms.com |
Market Trend Overview for BMY
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, BMY is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
BMY last closed at 58.94. The price is about 0.3 ATR above its recent average price (58.55), and the market is currently in a sideways market without a clear direction. Price at 58.94 is moving between minor support near 58.32 and minor resistance near 60.81. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside level is near 56.38. If price falls below this area, the current upward trend would likely weaken or break.
On 2026-03-18, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-03-25] Price moved quickly and looked strong, but participation was limited.Bearish signal near support (0.46 ATR away). Buyers may defend this level. Pattern is less clear, so strength is reduced.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is only slightly below the recent estimated cost basis of 59.27. Price is in the upper half of the main cost band (56.77 to 58.95), which is usually a healthier short-term location because price is holding the stronger side of recent trading activity. The lower down support area sits around 57.07 to 57.64. It looks more like a first buffer than a major floor. The higher up selling area sits around 59.52 to 59.95, so rebounds may begin to slow as price pushes into that zone. Recent positioning looks fairly balanced, with 41% in profit and 59% under water. From a trading point of view, the structure is still best read by comparing price with the main cost band first, then watching whether the lower support zone or higher supply zone becomes the next directional checkpoint.
Short Interest & Covering Risk for BMY
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 31%)
Structure Analysis
BMY Short positioning looks normal. Current days to cover is 2.6 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 13/100, DTC percentile 61%) with short positioning continuing to expand and liquidity softening modestly (volume -11%).
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.